[go: up one dir, main page]

MA26845A1 - Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4- - Google Patents

Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4-

Info

Publication number
MA26845A1
MA26845A1 MA26653A MA26653A MA26845A1 MA 26845 A1 MA26845 A1 MA 26845A1 MA 26653 A MA26653 A MA 26653A MA 26653 A MA26653 A MA 26653A MA 26845 A1 MA26845 A1 MA 26845A1
Authority
MA
Morocco
Prior art keywords
carboxyamino
ethyl
crystalline form
crystalline
Prior art date
Application number
MA26653A
Other languages
English (en)
French (fr)
Inventor
John Meldrum Allen Douglas
Anthony Appleton Troy
Lawrence Tickner Derek
Robinson Brostrom Lyle
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26845A1 publication Critical patent/MA26845A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)
MA26653A 1999-11-30 2002-05-27 Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4- MA26845A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
MA26845A1 true MA26845A1 (fr) 2004-12-20

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26653A MA26845A1 (fr) 1999-11-30 2002-05-27 Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4-

Country Status (28)

Country Link
EP (1) EP1246804A1 (et)
JP (1) JP2003515592A (et)
KR (1) KR20020058057A (et)
CN (1) CN1402711A (et)
AP (1) AP2002002531A0 (et)
AU (1) AU1048801A (et)
BG (1) BG106854A (et)
BR (1) BR0015836A (et)
CA (1) CA2392979A1 (et)
CO (1) CO5271716A1 (et)
EA (1) EA200200510A1 (et)
EC (1) ECSP003792A (et)
EE (1) EE200200277A (et)
GT (1) GT200000199A (et)
HU (1) HUP0203521A2 (et)
IL (1) IL149097A0 (et)
IS (1) IS6338A (et)
MA (1) MA26845A1 (et)
MX (1) MXPA02005354A (et)
NO (1) NO20022558D0 (et)
OA (1) OA12099A (et)
PA (1) PA8506301A1 (et)
PE (1) PE20010904A1 (et)
PL (1) PL355892A1 (et)
TN (1) TNSN00231A1 (et)
TR (1) TR200201446T2 (et)
UY (1) UY26454A1 (et)
WO (1) WO2001040190A1 (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (es) * 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
RU2293078C2 (ru) 2002-08-30 2007-02-10 Джапан Тобакко Инк. Соединения дибензиламина, фармацевтическая композиция и терапевтический или профилактический агент на их основе, способ лечения или профилактики гиперлипидемии или артериосклероза
CA2500582A1 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ATE461700T1 (de) 2002-12-20 2010-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
EP1622872A1 (en) * 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
HRP20090581T1 (hr) 2003-10-08 2009-12-31 Eli Lilly And Company Spojevi i postupci za liječenje dislipidemije
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
MXPA06014716A (es) * 2004-06-24 2007-03-12 Lilly Co Eli Compuestos y metodos para el tratamiento de dislipidemia.
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
PT3174995T (pt) 2014-07-30 2020-10-15 Hoffmann La Roche Marcadores genéticos para prever o tipo de resposta ao tratamento com um fármaco de aumento do hdl ou mimetizador do hdl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
IL149097A0 (en) 2002-11-10
BR0015836A (pt) 2002-08-06
HUP0203521A2 (hu) 2003-02-28
PE20010904A1 (es) 2001-09-10
JP2003515592A (ja) 2003-05-07
CA2392979A1 (en) 2001-06-07
PA8506301A1 (es) 2002-08-26
BG106854A (bg) 2002-12-29
ECSP003792A (es) 2002-04-23
WO2001040190A1 (en) 2001-06-07
KR20020058057A (ko) 2002-07-12
CN1402711A (zh) 2003-03-12
EP1246804A1 (en) 2002-10-09
UY26454A1 (es) 2001-07-31
EE200200277A (et) 2003-10-15
MXPA02005354A (es) 2002-12-11
OA12099A (en) 2006-05-04
GT200000199A (es) 2002-05-23
NO20022558L (no) 2002-05-29
PL355892A1 (en) 2004-05-31
TR200201446T2 (tr) 2002-11-21
IS6338A (is) 2002-04-12
AU1048801A (en) 2001-06-12
EA200200510A1 (ru) 2002-10-31
TNSN00231A1 (fr) 2002-05-30
AP2002002531A0 (en) 2002-06-30
CO5271716A1 (es) 2003-04-30
NO20022558D0 (no) 2002-05-29

Similar Documents

Publication Publication Date Title
MA26845A1 (fr) Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4-
MA27349A1 (fr) Composition cristalline renfermant de l'escitalopram.
DZ2817A1 (fr) Forme polymorphe de l'hydrogénosulfate de clopidogrel.
HUP0100779A3 (en) Novel derivatives of 3,3-diphenylpropylamines
ID26743A (id) Turunan 1,2,4,5-tetrahidro-benzo [d] azepin
EP1268688A4 (en) INK COMPOSITIONS
NO20012857L (no) Galantaminsammensetning med kontrollert frigivelse
DE69933287D1 (de) 12,13-modifizierte epothilon-derivate
HUP0204034A3 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
MA26500A1 (fr) Forme nouvelle de s-omerprazole
DE69936011D1 (de) Graviersystem
ID26310A (id) Produksi kontinyu 1,3-dioksolan-2-ona
AR027907A1 (es) Composicion de liberacion controlada
DE69919255D1 (de) Graviervorrichtung
DE59907008D1 (de) Farbwerk
PL342060A1 (en) Derivatives of 1,3,4-oxadiaxolone
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
ID28601A (id) Proses penyiapan senyawa-senyawa 1,4-dihidropiridin
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
ID22456A (id) Proses pembuatan diester-diester 2,3,5-trimetilhidrokuinon
DE59902774D1 (de) Gravierorgan
ID27686A (id) Turunan 3-(2-okso-[1,3]bipirolidinil-3-ildenametil)-sefem
ATE238335T1 (de) 5' deoxycytidin-derivative
DE69917392D1 (de) Kristalline Polymerzusammensetzung
DE59905687D1 (de) Gravierorgan